This inventor holds 2 USPTO granted patents. Top assignee: Nippon Chemiphar Co., Ltd.. Active years: 1985-1986.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Sakura, JP (1985)
- Ibaragi, JP (1986)
Company Filing History:
Years Active: 1985-1986
Title: Tomoh Masaki: Innovator in Pharmaceutical Chemistry
Introduction
Tomoh Masaki is a notable inventor based in Sakura, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly through his innovative work on piperazine derivatives. With a total of 2 patents to his name, Masaki's inventions are aimed at improving medical treatments.
Latest Patents
Masaki's latest patents focus on piperazine derivatives and their medicinal applications. One of his key inventions discloses a compound with a specific formula, where R¹ can be a hydrogen atom or a straight or branched chain alkyl group containing 1 to 4 carbon atoms. R² is similarly defined, and the compound is designed to be effective in inhibiting myocardial infarction. The patent also outlines a process for producing this compound and a medicine that incorporates it, showcasing its potential therapeutic benefits.
Career Highlights
Tomoh Masaki is currently associated with Nippon Chemiphar Co., Ltd., where he continues to advance his research and development efforts. His work has garnered attention for its innovative approach to addressing critical health issues through chemical compounds.
Collaborations
Masaki collaborates with esteemed colleagues, including Mitsuo Masaki and Koichi Kumakura, to further enhance the impact of his research. Their combined expertise contributes to the development of effective pharmaceutical solutions.
Conclusion
In summary, Tomoh Masaki is a distinguished inventor whose work in pharmaceutical chemistry has led to valuable innovations. His contributions, particularly in the area of piperazine derivatives, hold promise for improving medical treatments and addressing significant health challenges.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile